Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts
This article was originally published in The Gray Sheet
Executive Summary
Developers of "artificial pancreas" devices for treating type 1 diabetes may gain insight from new FDA draft guidance on clinical trial design, but patients and advocates say the agency is standing in the way of greater advances in the space.